10 citations
,
October 2009 in “Clinical Therapeutics” Finasteride 5-mg oral disintegrating tablets and standard tablets are bioequivalent in healthy adult male Han Chinese volunteers.
94 citations
,
July 1991 in “Clinical endocrinology” Cyproterone acetate at 2mg daily is as effective as higher doses for treating excessive hair growth in women.
September 2022 in “Journal of Sulaimani Medical College” The combination treatment showed some improvement but wasn't significantly better than using betamethasone valerate alone.
June 2019 in “Poster presentations” Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.
March 2005 in “European Urology Supplements” August 2025 in “JAAD International” Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
1 citations
,
July 2016 in “PubMed” Once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution are similarly effective and safe for female pattern hair loss.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
26 citations
,
January 2009 in “Transfusion Medicine and Hemotherapy” Donors on most medications can donate certain blood products without waiting, except for specific drugs that need a waiting period.
April 2023 in “Journal of Investigative Dermatology” Narrowband Ultraviolet B treatment can significantly reduce anxiety in psoriasis patients, but it doesn't significantly affect depression.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
February 2026 in “Clinical and Experimental Dermatology” Bicalutamide improved hair growth more than spironolactone in women with hair loss.
17 citations
,
May 1975 in “Clinical Pharmacology & Therapeutics”
1 citations
,
May 2023 in “Journal of the American Academy of Dermatology” Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.
January 2001 in “대한피부과학회지” Oral minipulse therapy with betamethasone effectively promotes hair regrowth in alopecia areata with fewer side effects.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
October 2025 in “Reactions Weekly”
January 2011 in “Reactions Weekly” St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
July 2026 in “Journal of the American Academy of Dermatology” 8 citations
,
November 2011 in “Journal of Medical Case Reports” Bupropion may help treat trichotillomania when fluoxetine doesn't work.
March 2023 in “Brazilian Journal of Health Review” The combination tablet of finasteride and doxazosin works the same as taking each drug separately.
July 2025 in “Reactions Weekly”
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
Taking too much biotin can mess up blood test results, which might lead to wrong diagnoses and treatments.
September 2024 in “Journal of the American Academy of Dermatology” Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.